Hangzhou Alltest Biotech Co. Ltd. A
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; flu… Read more
Hangzhou Alltest Biotech Co. Ltd. A - Asset Resilience Ratio
Hangzhou Alltest Biotech Co. Ltd. A (688606) has an Asset Resilience Ratio of 34.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Hangzhou Alltest Biotech Co. Ltd. A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hangzhou Alltest Biotech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.47 Billion | 34.75% |
| Total Liquid Assets | CN¥1.47 Billion | 34.75% |
Asset Resilience Insights
- Very High Liquidity: Hangzhou Alltest Biotech Co. Ltd. A maintains exceptional liquid asset reserves at 34.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hangzhou Alltest Biotech Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Hangzhou Alltest Biotech Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931 |
Medical Instruments & Supplies | 0.06% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 35.75% |
|
Blue Sail Medical Co Ltd
SHE:002382 |
Medical Instruments & Supplies | 5.12% |
|
Allmed Medical Products Co Ltd Class A
SHE:002950 |
Medical Instruments & Supplies | 3.78% |
|
Inix Technologies Holdings Bhd
KLSE:0094 |
Medical Instruments & Supplies | 0.06% |
|
Focus Point Holdings Bhd
KLSE:0157 |
Medical Instruments & Supplies | 2.30% |
|
Careplus Group Bhd
KLSE:0163 |
Medical Instruments & Supplies | 4.91% |
|
LKL International Bhd
KLSE:0182 |
Medical Instruments & Supplies | 0.38% |
Annual Asset Resilience Ratio for Hangzhou Alltest Biotech Co. Ltd. A (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Hangzhou Alltest Biotech Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 39.59% | CN¥1.66 Billion | CN¥4.19 Billion | +3.85pp |
| 2023-12-31 | 35.75% | CN¥1.47 Billion | CN¥4.12 Billion | -3.25pp |
| 2022-12-31 | 39.00% | CN¥1.83 Billion | CN¥4.70 Billion | +19.54pp |
| 2021-12-31 | 19.46% | CN¥780.20 Million | CN¥4.01 Billion | -16.59pp |
| 2020-12-31 | 36.05% | CN¥415.00 Million | CN¥1.15 Billion | +17.41pp |
| 2019-12-31 | 18.65% | CN¥62.00 Million | CN¥332.50 Million | -- |